RE: Hype vs Substance.27 Nov 2020 19:55
Agreed Traderb.....we should also remind ourselves....
For food intolerance, finnCap believes revenues could be in the region of £6-£12mln, generating a gross profit of £4-£8mln. Based on a 10-times enterprise multiple, it reckons the opportunity could ultimately be worth £40-£80mln, or £30-£60mln today.
The two new COVID revenue streams (Mologic and UK Rapid Test Consortium) might add as much as £37mln to the top line, which finnCap values at £75-£110mln. Finally, it said the VISITECT CD4 test opportunity is “worth £45-£75mln today”.
The above provides a sum of the parts valuation well in excess of the current Omega Diagnostics market capitalisation of £107mln, finnCap pointed out.